135 related articles for article (PubMed ID: 35981366)
1. [Predictive Value of Acute Phase Proteins on the Prognosis of Patients with Acute Myeloid Leukemia].
Wu XJ; Wang YQ; Yang XY; Lin XS; Qiu MH
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2022 Aug; 30(4):1086-1093. PubMed ID: 35981366
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of NPM1 mutations and FLT3 internal tandem duplications in Egyptian patients with cytogenetically normal acute myeloid leukemia.
Shamaa S; Laimon N; Aladle DA; Azmy E; Elghannam DM; Salem DA; Taalab MM
Hematology; 2014 Jan; 19(1):22-30. PubMed ID: 23540998
[TBL] [Abstract][Full Text] [Related]
3. [Analysis of induction efficacy and prognostic factors in FLT3-ITD positive acute myeloid leukemia in the real world].
Jia JS; Zhu HH; Gong LZ; Zhao T; Wang J; Jiang Q; Huang XJ; Jiang H
Zhonghua Xue Ye Xue Za Zhi; 2019 May; 40(5):398-403. PubMed ID: 31207705
[No Abstract] [Full Text] [Related]
4. [Clinical features and prognostic factors in adult acute myeloid leukemia patients with FLT3-ITD and CEBPA gene co-mutation].
Pei RR; Zhang RH; Yu JF; Jiang ZX; Sun H; Wan DM; Xie XS; Liu YF; Li T; Sun L
Zhonghua Xue Ye Xue Za Zhi; 2020 Apr; 41(4):297-301. PubMed ID: 32447933
[No Abstract] [Full Text] [Related]
5. The prognosis predictive value of FMS-like tyrosine kinase 3-internal tandem duplications mutant allelic ratio (FLT3-ITD MR) in patients with acute myeloid leukemia detected by GeneScan.
Lyu M; Liao H; Shuai X; Jin Y; Su J; Zheng Q
Gene; 2020 Feb; 726():144195. PubMed ID: 31669649
[TBL] [Abstract][Full Text] [Related]
6. [Correlation of MiR-34a/b/c Expression with Treatment Response and Prognosis of Elderly Patients with Acute Myeloid Leukemia].
Li H; Bao HX; Qin J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2020 Apr; 28(2):476-483. PubMed ID: 32319382
[TBL] [Abstract][Full Text] [Related]
7. [Clinical characteristics and prognosis of 34 cases of acute myeloid leukemia with FLT3 internal tandem duplication and MLL gene rearrangement].
Zhou JR; Zhang X; Zhao YL; Yang JF; Zhang JP; Cao XY; Lu Y; Liu DY; Lyu FY; Ouyang J; Lu PH
Zhonghua Xue Ye Xue Za Zhi; 2018 Sep; 39(9):751-756. PubMed ID: 30369187
[No Abstract] [Full Text] [Related]
8. The effect of the detection of minimal residual disease for the prognosis and the choice of post-remission therapy of intermediate-risk acute myeloid leukemia without FLT3-ITD, NPM1 and biallelic CEBPA mutations.
Zheng WS; Hu YL; Guan LX; Peng B; Wang SY
Hematology; 2021 Dec; 26(1):179-185. PubMed ID: 33594943
[TBL] [Abstract][Full Text] [Related]
9. High CD200 expression is associated with poor prognosis in cytogenetically normal acute myeloid leukemia, even in FlT3-ITD-/NPM1+ patients.
Tiribelli M; Raspadori D; Geromin A; Cavallin M; Sirianni S; Simeone E; Bocchia M; Fanin R; Damiani D
Leuk Res; 2017 Jul; 58():31-38. PubMed ID: 28407515
[TBL] [Abstract][Full Text] [Related]
10. Predictive value of pretransplantation molecular minimal residual disease assessment by WT1 gene expression in FLT3-positive acute myeloid leukemia.
Candoni A; De Marchi F; Zanini F; Zannier ME; Simeone E; Toffoletti E; Chiarvesio A; Cerno M; Filì C; Patriarca F; Fanin R
Exp Hematol; 2017 May; 49():25-33. PubMed ID: 28159598
[TBL] [Abstract][Full Text] [Related]
11. Clinical significance of FLT3-ITD/CEBPA mutations and minimal residual disease in cytogenetically normal acute myeloid leukemia after hematopoietic stem cell transplantation.
Wang H; Li XQ; Chu TT; Han SY; Qi JQ; Tang YQ; Qiu HY; Fu CC; Tang XW; Ruan CG; Wu DP; Han Y
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2659-2670. PubMed ID: 33550446
[TBL] [Abstract][Full Text] [Related]
12. Analysis of FLT3-Activating Mutations in Patients With Acute Myelogenous Leukemia in Jordan: Association With FAB Subtypes and Identification of Subgroups With Poor Prognosis.
Halahleh K; Taqash A; Abdelkhaleq H; Manasrah M; Marie L; Al-Rabi K
Clin Lymphoma Myeloma Leuk; 2021 Jul; 21(7):e588-e597. PubMed ID: 33811005
[TBL] [Abstract][Full Text] [Related]
13. Outcome of FLT3-ITD-positive acute myeloid leukemia: impact of allogeneic stem cell transplantation and tyrosine kinase inhibitor treatment.
Fleischmann M; Schnetzke U; Schrenk KG; Schmidt V; Sayer HG; Hilgendorf I; Hochhaus A; Scholl S
J Cancer Res Clin Oncol; 2017 Feb; 143(2):337-345. PubMed ID: 27778197
[TBL] [Abstract][Full Text] [Related]
14. Concomitant ABCG2 overexpression and FLT3-ITD mutation identify a subset of acute myeloid leukemia patients at high risk of relapse.
Tiribelli M; Geromin A; Michelutti A; Cavallin M; Pianta A; Fabbro D; Russo D; Damante G; Fanin R; Damiani D
Cancer; 2011 May; 117(10):2156-62. PubMed ID: 21523728
[TBL] [Abstract][Full Text] [Related]
15. [
Tang SS; Ye YX; Zhou YH; Zhou Y; Zhou J; Yu J; Guo MY; Lu XJ; Ying BW
Sichuan Da Xue Xue Bao Yi Xue Ban; 2016 Nov; 47(6):926-930. PubMed ID: 28598126
[TBL] [Abstract][Full Text] [Related]
16. FLT3-ITD and CD135 Over-Expression are Frequent Findings of Poor Survival in Adult Patients with Acute Leukemias.
Vela-Ojeda J; Cardenas PV; Garcia-Ruiz Esparza MA; Montiel Cervantes LA; Chavez JG; Caballero AH; Majluf-Cruz A; Vega-López A; Reyes-Maldonado E
Arch Med Res; 2021 Feb; 52(2):217-223. PubMed ID: 33109387
[TBL] [Abstract][Full Text] [Related]
17. [Prognostic significance of early assessment of minimal residual disease in acute myeloid leukemia with mutated NPM1 patients].
Zhao T; Zhu HH; Wang J; Jia JS; Yang SM; Jiang H; Lu J; Chen H; Xu LP; Zhang XH; Jiang B; Ruan GR; Wang DB; Huang XJ; Jiang Q
Zhonghua Xue Ye Xue Za Zhi; 2017 Jan; 38(1):10-16. PubMed ID: 28219218
[No Abstract] [Full Text] [Related]
18. Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD.
Ho AD; Schetelig J; Bochtler T; Schaich M; Schäfer-Eckart K; Hänel M; Rösler W; Einsele H; Kaufmann M; Serve H; Berdel WE; Stelljes M; Mayer J; Reichle A; Baldus CD; Schmitz N; Kramer M; Röllig C; Bornhäuser M; Thiede C; Ehninger G;
Biol Blood Marrow Transplant; 2016 Mar; 22(3):462-9. PubMed ID: 26551637
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of the CFA ratio for newly diagnosed acute myeloid leukemia: A multicenter retrospective study.
Sakuma T; Fujisawa S; Tanaka M; Hagihara M; Fujita H; Fujimaki K; Katsuki K; Akimoto M; Tanaka M; Matsumura A; Teshigawara H; Suzuki T; Teranaka H; Nakajima Y; Miyazaki T; Tachibana T; Matsumoto K; Sakai R; Kanamori H; Nakajima H
Hematol Oncol; 2024 Jan; 42(1):e3228. PubMed ID: 37731313
[TBL] [Abstract][Full Text] [Related]
20. Prognostic significance of FLT3-ITD length in AML patients treated with intensive regimens.
Castaño-Bonilla T; Alonso-Dominguez JM; Barragán E; Rodríguez-Veiga R; Sargas C; Gil C; Chillón C; Vidriales MB; García R; Martínez-López J; Ayala R; Larrayoz MJ; Anguita E; Cuello R; Cantalapiedra A; Carrillo E; Soria-Saldise E; Labrador J; Recio I; Algarra L; Rodríguez-Medina C; Bilbao-Syeiro C; López-López JA; Serrano J; De Cabo E; Sayas MJ; Olave MT; Sánchez-García J; Mateos M; Blas C; López-Lorenzo JL; Lainez-Gonzalez D; Serrano J; Martínez-Cuadrón D; Sanz MA; Montesinos P
Sci Rep; 2021 Oct; 11(1):20745. PubMed ID: 34671057
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
